Moderna Shares Jump After Announcing Q4 2021 Earnings, US$19 Billion Advanced Sales

Moderna Inc (Nasdaq: MRNA) announced this morning its Q4 and full-year 2021 earnings. The vaccine manufacturer earned US$7.21 billion in revenue, beating the consensus estimates of US$6.78 billion.

The quarterly revenue was heavily driven by the sale of around 297 million doses of its COVID-19 vaccine. This compares to US$571 million in revenue, including the sale of 13 million doses in the year-ago period.

Source: Hypercharts

The firm also recorded a quarterly net income of US$4.87 billion compared to a loss of US$272 million last year. This translates to US$11.29 earnings per diluted share, also beating the estimates of US$9.90 per share.

For 2021, the company recorded US$18.47 billion in revenue, including product sales from 807 million COVID-19 doses. This is an increase from 2020’s US$803 million in revenue. Meanwhile, net income for the year came in at US$12.20 billion compared to last year’s loss of US$747 million.

The company added that the “record product sales” started during the year after being granted an emergency use authorization for its vaccine from US FDA and Health Canada.

Source: Hypercharts

While the biotech firm previously estimated US$17 billion in product sales in 2022, it announced today a total of US$19 billion in signed advanced purchase agreements for the year–while still currently in active discussions for additional orders.

The company also plans to launch a share buyback program of around US$3 billion in total. Its previous US$1 billion program announced in August 2021 has already been fully subscribed by January 2022, according to the company.

Following the company’s release, shares have gone up as much as 5% pre-market.

In an interview with CNBC, CEO Stephane Bancel believes that COVID-19 has “a high probability” of moving into an endemic phase.

“There’s an 80% chance that as omicron evolves or SarsCov-2 virus evolves, we are going to see less and less virulent viruses,” said Bancel. Inversely, there’s a “20% scenario where we see a next mutation which is more virulent than omicron.”

The company also mentioned that its COVID-19 vaccine Spikevax has already recorded “firm orders” from the United Kingdom, Canada, Taiwan, and Kuwait in 2023.

Last week, the firm announced its plans to expand its manufacturing into Spain and to establish subsidiaries in Hong Kong, Taiwan, Singapore, and Malaysia.

Moderna last traded at $135.73 on the Nasdaq.


Information for this briefing was found via CNBC and the companies mentioned. The author has no securities or affiliations related to this organization. Not a recommendation to buy or sell. Always do additional research and consult a professional before purchasing a security. The author holds no licenses.

Leave a Reply

Video Articles

Endeavour Mining Q1 Earnings: Cash Flow Is King

G Mining Oko West Feasibility: Move Fast, Break.. Nothing?

New Gold Q1 Earnings: What’s Behind The Market’s Surprising Reaction?

Recommended

First Majestic Posts Record Cash Flows In Q1 As Production Costs Fall

Brazil Potash Secures Funding In Support Of US$2.5 Billion Autozales Project

Related News

New COVID Variant Sweeps China, Is North America Next?

Remarkably, the world could be facing another bout with COVID this year, and with negative...

Thursday, May 25, 2023, 07:35:00 AM

No, The CEO Of Moderna Didn’t Just Dump $400 Million In Shares

The trouble with social media, is that it’s a big game of telephone. One individual...

Sunday, February 13, 2022, 02:50:29 PM

Moderna To Construct Manufacturing Facility In Australia Under New Strategic Partnership

Moderna Inc (NASDAQ: MRNA) is officially going to the land down under. The company late...

Thursday, March 24, 2022, 08:53:32 AM

Moderna and Merck & Co: mRNA Cancer Vaccine Shows “Highly Encouraging Results,” Shares Rise

On Tuesday, Moderna (NASDAQ: MRNA) announced that their personalized cancer-vaccine program was successful in a...

Wednesday, December 14, 2022, 01:06:00 PM

Internal Moderna Report Tags Elon Musk, Novak Djokovic, and Russell Brand as ‘High Risk’

Moderna (NASDAQ: MRNA), the Boston-based pharmaceutical company known for its mRNA Covid-19 vaccine, has reportedly...

Tuesday, November 28, 2023, 01:06:00 PM